Literature DB >> 15618147

Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine lyme arthritis.

Aruna K Behera1, Ethan Hildebrand, Joanna Scagliotti, Allen C Steere, Linden T Hu.   

Abstract

Matrix metalloproteinases (MMPs) are induced from host tissues in response to Borrelia burgdorferi. Upregulation of MMPs may play a role in the dissemination of the organism through extracellular matrix tissues, but it can also result in destructive pathology. Although mice are a well-accepted model for Lyme arthritis, there are significant differences compared to human disease. We sought to determine whether MMP expression could account for some of these differences. MMP expression patterns following B. burgdorferi infection were analyzed in primary human chondrocytes, synovial fluid samples from patients with Lyme arthritis, and cartilage tissue from Lyme arthritis-susceptible and -resistant mice by using a gene array, real-time PCR, an enzyme-linked immunosorbent assay, and immunohistochemistry. B. burgdorferi infection significantly induced transcription of MMP-1, -3, -13, and -19 from primary human chondrocyte cells. Transcription of MMP-10 and tissue inhibitor of metalloprotease 1 was increased with B. burgdorferi infection, but protein expression was only minimally increased. The synovial fluid levels of MMPs from patients with high and low spirochete burdens were consistent with results seen in the in vitro studies. B. burgdorferi-susceptible C3H/HeN mice infected with B. burgdorferi showed induction of MMP-3 and MMP-19 but no other MMP or tissue inhibitor of metalloprotease. As determined by immunohistochemistry, MMP-3 expression was increased only in chondrocytes near the articular surface. The levels of MMPs were significantly lower in the more Lyme arthritis-resistant BALB/c and C57BL/6 mice. Differences between human and murine Lyme arthritis may be related to the lack of induction of collagenases, such MMP-1 and MMP-13, in mouse joints.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618147      PMCID: PMC539001          DOI: 10.1128/IAI.73.1.126-134.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Authors:  M W Lark; E K Bayne; J Flanagan; C F Harper; L A Hoerrner; N I Hutchinson; I I Singer; S A Donatelli; J R Weidner; H R Williams; R A Mumford; L S Lohmander
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice.

Authors:  S W Barthold; D H Persing; A L Armstrong; R A Peeples
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

3.  Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease.

Authors:  P M Pennington; C D Allred; C S West; R Alvarez; A G Barbour
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

4.  Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  M S Klempner; R Noring; M P Epstein; B McCloud; R Hu; S A Limentani; R A Rogers
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

5.  Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.

Authors:  D Ahrens; A E Koch; R M Pope; M Stein-Picarella; M J Niedbala
Journal:  Arthritis Rheum       Date:  1996-09

6.  Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis.

Authors:  K Ohashi; R Kawai; M Hara; Y Okada; S Tachibana; Y Ogura
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

7.  Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis.

Authors:  J J Nocton; F Dressler; B J Rutledge; P N Rys; D H Persing; A C Steere
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

8.  Chronic Lyme borreliosis in the laboratory mouse.

Authors:  S W Barthold; M S de Souza; J L Janotka; A L Smith; D H Persing
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium.

Authors:  E M Gravallese; J M Darling; A L Ladd; J N Katz; L H Glimcher
Journal:  Arthritis Rheum       Date:  1991-09

10.  Studies on early events of Borrelia burgdorferi-induced cytokine production in immunodeficient SCID mice by using a tissue chamber model for acute inflammation.

Authors:  U Hurtenbach; C Museteanu; J Gasser; U E Schaible; M M Simon
Journal:  Int J Exp Pathol       Date:  1995-04       Impact factor: 1.925

View more
  30 in total

1.  CD14 signaling reciprocally controls collagen deposition and turnover to regulate the development of lyme arthritis.

Authors:  Bikash Sahay; Anju Singh; Arumugam Gnanamani; Rebeca L Patsey; J Edwin Blalock; Timothy J Sellati
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

3.  Gene profiling of the rat medial collateral ligament during early healing using microarray analysis.

Authors:  Connie S Chamberlain; Sabrina H Brounts; David G Sterken; Kevin I Rolnick; Geoffrey S Baer; Ray Vanderby
Journal:  J Appl Physiol (1985)       Date:  2011-05-19

4.  Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis.

Authors:  Jameson T Crowley; Klemen Strle; Elise E Drouin; Annalisa Pianta; Sheila L Arvikar; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  J Autoimmun       Date:  2016-02-26       Impact factor: 7.094

5.  Interleukin-10 alters effector functions of multiple genes induced by Borrelia burgdorferi in macrophages to regulate Lyme disease inflammation.

Authors:  Aarti Gautam; Saurabh Dixit; Mario T Philipp; Shree R Singh; Lisa A Morici; Deepak Kaushal; Vida A Dennis
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

6.  Protease-stable polycationic photosensitizer conjugates between polyethyleneimine and chlorin(e6) for broad-spectrum antimicrobial photoinactivation.

Authors:  George P Tegos; Masahiro Anbe; Changming Yang; Tatiana N Demidova; Minahil Satti; Pawel Mroz; Sumbul Janjua; Faten Gad; Michael R Hamblin
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Global transcriptome analysis of Borrelia burgdorferi during association with human neuroglial cells.

Authors:  Jill A Livengood; Virginia L Schmit; Robert D Gilmore
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

8.  Borrelia burgdorferi BBB07 interaction with integrin alpha3beta1 stimulates production of pro-inflammatory mediators in primary human chondrocytes.

Authors:  Aruna K Behera; Enrique Durand; Carla Cugini; Styliani Antonara; Lori Bourassa; Ethan Hildebrand; Linden T Hu; Jenifer Coburn
Journal:  Cell Microbiol       Date:  2007-09-06       Impact factor: 3.715

9.  Activation of human monocytes by live Borrelia burgdorferi generates TLR2-dependent and -independent responses which include induction of IFN-beta.

Authors:  Juan C Salazar; Star Duhnam-Ems; Carson La Vake; Adriana R Cruz; Meagan W Moore; Melissa J Caimano; Leonor Velez-Climent; Jonathan Shupe; Winfried Krueger; Justin D Radolf
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823

10.  Novel Diagnosis of Lyme Disease: Potential for CAM Intervention.

Authors:  Aristo Vojdani; Frank Hebroni; Yaniv Raphael; Jonathan Erde; Bernard Raxlen
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.